Disease prevention medications
Pro Research Analysisby 
Searched over 200M research papers
Cardiovascular Disease Prevention Medications: Types and Effectiveness
Medications play a crucial role in both primary and secondary prevention of cardiovascular disease (CVD). For primary prevention, lipid-lowering drugs like statins and antiplatelet medications have shown benefits in reducing cardiovascular events and mortality, though the impact on all-cause mortality is less consistent across studies. Glucose-lowering medications also provide significant benefits for those at risk of CVD. However, non-pharmacological interventions such as diet and exercise, when used alone, generally show little or no significant benefit for major cardiovascular outcomes compared to medications 79.
For secondary prevention—preventing further events in people with established CVD—proven medications include antiplatelet drugs (like aspirin), statins, beta-blockers, and renin-angiotensin system (RAS) inhibitors (such as ACE inhibitors or ARBs). These medications are effective in reducing the risk of recurrent cardiovascular events and improving survival 2456.
Medication Adherence and Combination Therapies
Despite the proven benefits, adherence to preventive medications is often poor, especially in chronic patients who require multiple drugs. Poor adherence is linked to higher rates of recurrent events and increased healthcare costs 156. To address this, polypill strategies—combining several medications into a single tablet—have been developed. Polypills typically include an antiplatelet, a statin, and an antihypertensive, and have been shown to improve adherence and outcomes in CVD prevention 18.
Combination therapy is also recommended for hypertension management, often involving two or more classes of antihypertensive drugs. Newer medications, such as angiotensin receptor neprilysin inhibitors (ARNIs) and sodium glucose cotransporter 2 inhibitors (SGLT2i), are being explored for their broader benefits in patients with hypertension, heart failure, or diabetes .
Global Use and Access to Preventive Medications
The use of secondary prevention medications varies widely across countries and is generally suboptimal, especially in low- and middle-income countries (LMICs) and rural areas. In high-income countries, medication use is higher, but still not universal. In LMICs, the rates are much lower, with significant disparities between urban and rural populations 2345.
In China, for example, only about 22% of people with established CVD reported using either antiplatelet drugs or statins, with even lower rates among younger people, women, rural residents, and those with longer-standing disease . Globally, the use of secondary prevention medications has remained low over time, with little improvement, especially in lower-income settings .
Barriers and Facilitators to Medication Use
Barriers to optimal use of preventive medications include cost, lack of access, and health system factors. Full prescription coverage, reduced copayments, fixed-dose combination therapy (polypills), and patient counseling have been identified as effective strategies to improve adherence 810. The use of generic medications is particularly cost-effective and can save money for both patients and health systems .
Conclusion
Medications such as statins, antiplatelet agents, beta-blockers, and RAS inhibitors are effective for both primary and secondary prevention of cardiovascular disease. However, global use remains suboptimal, especially in low-resource settings. Improving access to affordable medications, promoting combination therapies like polypills, and addressing health system barriers are key strategies to enhance disease prevention and reduce the global burden of CVD 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic